- Home
- About Us
- Our Products
- Investors
- News
- New Product Pipeline
- Contact Us
Pharmaxis is a specialist pharmaceutical company that researches, develops and commercialises new therapies for undertreated respiratory diseases.
Founded on an Australian discovery, Pharmaxis' products are now available worldwide. 

The National Institute for Health and Clinical Excellence (NICE) in the U.K. has issued a positive recommendation for Bronchitol®, clearing the way for reimbursement by the National Health Service.

A drug discovered and developed in Australia has been listed on the PBS for the treatment of cystic fibrosis.![]()

Pharmaxis is pleased to announce the signing of a Financing Agreement with NovaQuest under which NovaQuest will invest up to US$40 million to support the continued development, manufacturing and commercialisation of Bronchitol for CF in the EU and US.